Display options
Cite
Nikitopoulou I, Manitsopoulos N, Kotanidou A, et al. Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice. Pulm Circ. 2019;9(4):2045894019881954doi: 10.1177/2045894019881954.
Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., & Orfanos, S. E. (2019). Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice. Pulmonary circulation, 9(4), 2045894019881954. https://doi.org/10.1177/2045894019881954
Nikitopoulou, Ioanna, et al. "Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice." Pulmonary circulation vol. 9,4 (2019): 2045894019881954. doi: https://doi.org/10.1177/2045894019881954
Nikitopoulou I, Manitsopoulos N, Kotanidou A, Tian X, Petrovic A, Magkou C, Ninou I, Aidinis V, Schermuly RT, Kosanovic D, Orfanos SE. Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice. Pulm Circ. 2019 Nov 15;9(4):2045894019881954. doi: 10.1177/2045894019881954. eCollection 2019. PMID: 31819797; PMCID: PMC6883672.
Copy Download .nbib Format: NLM
Share it on

Pulm Circ. 2019 Nov 15;9(4):2045894019881954. doi: 10.1177/2045894019881954. eCollection 2019.

Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice.

Pulmonary circulation

Ioanna Nikitopoulou, Nikolaos Manitsopoulos, Anastasia Kotanidou, Xia Tian, Aleksandar Petrovic, Christina Magkou, Ioanna Ninou, Vassilis Aidinis, Ralph T Schermuly, Djuro Kosanovic, Stylianos E Orfanos

Affiliations

  1. GP Livanos and M Simou Laboratories,1st Department of Critical Care & Pulmonary Services, Medical School, National & Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece.
  2. 1st Department of Critical Care & Pulmonary Services, Medical School, National & Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece.
  3. Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany.
  4. Department of Pathology, Evangelismos Hospital, Athens, Greece.
  5. Institute of Immunology, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
  6. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  7. 2nd Department of Critical Care, Medical School, National & Kapodistrian University of Athens, "Attikon" Hospital, Haidari, Athens, Greece.

PMID: 31819797 PMCID: PMC6883672 DOI: 10.1177/2045894019881954

Abstract

Pulmonary fibrosis is a progressive disease characterized by disruption of lung architecture and deregulation of the pulmonary function. Prostacyclin, a metabolite of arachidonic acid, is a potential disease mediator since it exerts anti-inflammatory and anti-fibrotic actions. We investigated the effect of treprostinil, a prostacyclin analogue, in bleomycin-induced experimental pulmonary fibrosis. Bleomycin sulfate or saline was administrated intratracheally to mice (

© The Author(s) 2019.

Keywords: bleomycin; fibrosis; inflammation; prostacyclin; pulmonary hypertension; treprostinil

References

  1. Mol Cell Biol. 2005 Jan;25(1):136-46 - PubMed
  2. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1778-83 - PubMed
  3. BMC Pulm Med. 2011 May 31;11:33 - PubMed
  4. PLoS One. 2016 Dec 19;11(12):e0167729 - PubMed
  5. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4 - PubMed
  6. Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L59-65 - PubMed
  7. Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50 - PubMed
  8. Exp Cell Res. 2007 Jul 1;313(11):2504-20 - PubMed
  9. Eur Respir J. 2010 Oct;36(4):808-18 - PubMed
  10. Respir Res. 2010 Mar 20;11:34 - PubMed
  11. Circ Res. 2010 Jul 23;107(2):252-62 - PubMed
  12. Pulm Pharmacol Ther. 2017 Feb;42:21-24 - PubMed
  13. Am J Respir Crit Care Med. 2006 May 1;173(9):1016-22 - PubMed
  14. Mucosal Immunol. 2017 Mar;10(2):341-351 - PubMed
  15. PLoS One. 2016 Feb 18;11(2):e0149652 - PubMed
  16. Prostaglandins Leukot Med. 1983 May;11(1):11-31 - PubMed
  17. J Immunol. 2007 Jan 15;178(2):702-10 - PubMed
  18. Eur Heart J. 2016 Jan 1;37(1):67-119 - PubMed
  19. Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L142-3 - PubMed
  20. Curr Opin Pulm Med. 2011 Sep;17(5):355-61 - PubMed
  21. Shock. 2003 Jul;20(1):29-34 - PubMed
  22. Respir Med. 2005 Jan;99(1):111-7 - PubMed
  23. Eur Respir J. 2013 Jan;41(1):165-76 - PubMed
  24. Eur Respir J. 2011 May;37(5):1119-27 - PubMed
  25. Eur Respir J. 2019 Jan 24;53(1):null - PubMed
  26. Am J Respir Cell Mol Biol. 2000 May;22(5):628-34 - PubMed
  27. Biotechniques. 2008 Apr;44(4):507-11, 514-7 - PubMed
  28. J Clin Invest. 2001 Jul;108(2):241-50 - PubMed
  29. J Clin Med. 2016 Dec 26;6(1):null - PubMed
  30. Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L144-56 - PubMed
  31. Respir Res. 2002;3:17 - PubMed
  32. Inflamm Res. 2011 Jul;60(7):655-63 - PubMed
  33. Cell Mol Life Sci. 2011 Oct;68(19):3201-7 - PubMed
  34. N Engl J Med. 2014 May 29;370(22):2071-82 - PubMed
  35. Pediatr Pulmonol. 2007 Nov;42(11):1048-56 - PubMed
  36. Core Evid. 2014 Jun 20;9:71-80 - PubMed
  37. Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L615-22 - PubMed
  38. Lancet Respir Med. 2019 Jun;7(6):497-508 - PubMed
  39. Am J Respir Cell Mol Biol. 2001 Mar;24(3):264-71 - PubMed
  40. Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1046-56 - PubMed
  41. Br J Pharmacol. 2009 Feb;156(3):534-44 - PubMed
  42. Am J Respir Crit Care Med. 2006 Oct 1;174(7):803-9 - PubMed
  43. Br J Pharmacol. 2013 Nov;170(6):1210-20 - PubMed
  44. Am J Physiol Lung Cell Mol Physiol. 2002 Aug;283(2):L428-32 - PubMed
  45. Pulm Pharmacol Ther. 2018 Apr;49:95-103 - PubMed
  46. FASEB J. 2002 Dec;16(14):1949-51 - PubMed
  47. Eur Respir J. 2019 Jan 24;53(1):null - PubMed
  48. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 1;307(9):L681-91 - PubMed
  49. J Cell Biochem. 1998 Nov 1;71(2):254-63 - PubMed
  50. Clin Med Insights Circ Respir Pulm Med. 2016 Dec 08;9(Suppl 1):179-185 - PubMed
  51. PLoS Med. 2005 Sep;2(9):e251 - PubMed
  52. Am J Respir Cell Mol Biol. 2011 Sep;45(3):445-52 - PubMed
  53. J Biol Chem. 2002 Sep 6;277(36):33344-8 - PubMed
  54. Am J Physiol Lung Cell Mol Physiol. 2011 Nov;301(5):L645-55 - PubMed
  55. PLoS One. 2013 Sep 17;8(9):e75783 - PubMed
  56. Shock. 2002 Jul;18(1):75-81 - PubMed
  57. J Clin Invest. 1995 Apr;95(4):1861-8 - PubMed
  58. Eur Respir J. 2010 Dec;36(6):1302-14 - PubMed
  59. Am J Respir Cell Mol Biol. 2012 May;46(5):677-86 - PubMed
  60. Respiration. 2018;95(2):122-136 - PubMed

Publication Types